ARV | New HIV Drugs v2

The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study

This slide deck walks through the initial results of the Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO)...

EGPAF Guidance and Algorithm for Follow-Up of Children After Starting or Transitioning to pDTG

The purpose of this guidance from EGPAF is to aid health care workers and support caregivers and children initiated on, or switched to,...

GAP-f pDTG Implementation Considerations for National Programmes

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

Adult DRV/r (400/50mg) Clinical Action Memo

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

CHAI DRV/r 2L Product Profile

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

EGPAF Guidance for Pediatric ARV Quantification and Supply Planning

This guidance from EGPAF is intended for national program managers; technical and clinical advisors; procurement entities; funding...

Pediatric DTG Healthcare Worker Resources

CHAI has developed new resources to support healthcare worker decision-making and counselling around pDTG. pDTG HCW Worker Overview Video...

Pediatric DTG Introduction: Transition Plan Templates

Fillable report and presentation template for governments to adjust as needed for introduction of pediatric DTG. English | French

Community Resources for Pediatric DTG Scale-Up

Optimal and FASTER CAB members, with technical support from CHAI, developed a multi-media package of treatment literacy and advocacy...

2021 WHO Optimal Formulary and Limited-Use List for ARVs for Children

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for...

Pediatric DTG Clinical Studies Repository

A CHAI-curated repository of clinical studies in the development and implementation of pediatric DTG.

Optimizing 2L HIV Treatment with DTG-based Regimens

This memo highlights the patient benefits, cost savings and improved supply security associated with proactively switching eligible 2L...

TLD Resources

CHAI's TLD resources help countries in creating the best plan for TLD introduction. CHAI TLD Clinical Action Memo CHAI DTG Use In Women...

HIV New Product Introduction Toolkit